AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26434382
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL normal saline)
Trial: 25034216
Drug: Simultaneous initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Simultaneous initiation of insulin pump therapy (Medtronic Veo©) and continuous glucose monitoring (CGM) (Enlite©)
Trial: 25034216
Drug: Standard pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pump therapy with delayed CGM introduction
Trial: 17118998
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg TAK-677 BID (n = 21)
Trial: 17118998
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg TAK-677 BID (n = 22)
Trial: 8081529
Drug: Sustained-release magnesium
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release magnesium chloride (Slo-Mag), 384 mg/d
Trial: 4552591
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (bethanidine, debrisoquine, guanethidine)
Trial: 28968163
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus a nonsteroidal aromatase inhibitor (150 mg twice daily continuous schedule)
Trial: 28968163
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus a nonsteroidal aromatase inhibitor
Trial: 22975340
Drug: Dengue vaccine
RxNorm normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue vaccine (3 injections at months 0, 6, and 12)
Trial: 22975340
Drug: Control (rabies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rabies vaccine or placebo)
Trial: 10449888
Drug: valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan (80 mg/160 mg q.d.)
Trial: 10449888
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg/100 mg q.d.)
Trial: 577626
Drug: Streptokinase ('Kabikinase')
RxNorm normalized name: streptokinase Injectable Solution [Kabikinase]
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase ('Kabikinase') followed by oral anticoagulant therapy
Trial: 577626
Drug: Ancrod ('Arvin')
RxNorm normalized name: ancrod
DrugBank: Ancrod (DB05099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ancrod ('Arvin') for 6 days followed by oral anticoagulant therapy
Trial: 577626
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral anticoagulant therapy only)
Trial: 577626
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and ancrod treatments
Trial: 30956267
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg/day
Trial: 30956267
Drug: Carvedilol 20
RxNorm normalized name: Carvedilol 20mg Oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 20 mg/day
Trial: 28253389
Drug: Drug-induced sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced sleep endoscopy with polygraphic monitoring (DISE-PG)
Trial: 24010992
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg sublingual nitroglycerin tablet
Trial: 24010992
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg sublingual nitroglycerin tablet
Trial: 24010992
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet of isosorbide mononitrate
Trial: 24010992
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg nitroglycerin transdermal patch (used for 8 h)
Trial: 24010992
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of nitroglycerin ointment
Trial: 21293309
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 80 mg/day
Trial: 19298581
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg once daily for 6 months
Trial: 19298581
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg once daily for 6 months
Trial: 15134122
Drug: HIV prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV prevention messages disseminated through community popular opinion leaders (CPOLs); specific details on dosage and duration not available.
Trial: 11483788
Drug: Daily antiinflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antiinflammatory medications (mostly cromolyn sodium)
Trial: 11483788
Drug: Daily antiinflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antiinflammatory medications
Trial: 9891542
Drug: Multi-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug regimens
Trial: 9891542
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent treatment (usually BCNU)
Trial: 1284158
Drug: Gallopamil 50
RxNorm normalized name: gallopamil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 50 mg t.i.d. (days 8-14)
Trial: 6531964
Drug: Suckling mouse
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suckling mouse brain vaccine (SMBV)
Trial: 6531964
Drug: Fetal bovine
RxNorm normalized name: Fetal Bovine Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal bovine kidney vaccine (FBKV) administered subcutaneously
Trial: 6531964
Drug: Fetal bovine
RxNorm normalized name: Fetal Bovine Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal bovine kidney vaccine (FBKV) administered intramuscularly
Trial: 30095354
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT-A) injection plus rehabilitation therapy
Trial: 26963844
Drug: Gabapentin (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (3600 mg daily)
Trial: 23084383
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for retinopathy of prematurity (ROP)
Trial: 17438101
Drug: Interferon-alpha2b therapy
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2b therapy
Trial: 11451596
Drug: 0.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/day rhGH during hospitalization
Trial: 10806764
Drug: Nao Yi-an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nao Yi-an granule (Chinese medicine group, CMG)
Trial: 10806764
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (western medicine group, WMG)
Trial: 2575983
Drug: nifedipine 20mg
RxNorm normalized name: NIFEDIPINE 20MG CAP
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine 20mg twice daily
Trial: 28701090
Drug: Transference Focused
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transference Focused Psychotherapy (TFP) combined with group skills training from Dialectic Behavior Therapy (DBT)
Trial: 26553085
Drug: Intravenous Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Dexamethasone (8 mg)
Trial: 26553085
Drug: Control (distilled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (distilled water, 8 mg)
Trial: 22279697
Drug: Literal adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literal adherence for pharmacotherapy initiations
Trial: 22279697
Drug: Literal adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literal adherence for drug up-titrations
Trial: 22279697
Drug: Substitute adherence
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitute adherence for drug up-titrations
Trial: 16490876
Drug: 200-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-microg dose of mometasone furoate nasal spray administered once daily
Trial: 16490876
Drug: 200-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-microg dose of mometasone furoate nasal spray administered twice daily
Trial: 16490876
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered in the morning and evening
Trial: 15214595
Drug: Systemically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically administered 5-FU
Trial: 15214595
Drug: HAI chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI chemotherapy
Trial: 11141713
Drug: Preventive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive management (0.45% saline intravenously, mannitol 20% 250 mL i.v., furosemide 80 mg i.v., dopamine 3 g/Kg/min i.v.)
Trial: 16250725
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment package
Trial: 7930276
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/day (increased to 10 mg/day after 4 weeks)
Trial: 2843341
Drug: Lisinopril +
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril + HCTZ
Trial: 2843341
Drug: All other
RxNorm normalized name: ALL OTHER THERAPEUTIC PRODUCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All other agents
Trial: 31635497
Drug: BCX7353 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX7353 (oral plasma kallikrein inhibitor), taken as an oral capsule, once daily.
Trial: 29231583
Drug: Acupoint plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint plaster therapy with midnight-noon ebb-flow hour-prescription method
Trial: 29231583
Drug: Traditional acupoint
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional acupoint plaster therapy
Trial: 19200622
Drug: Tamsulosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin plus ibuprofen and oxycodone
Trial: 19200622
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and oxycodone alone
Trial: 17405199
Drug: Transdermal anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal anaesthesia using EMLA applied transcutaneously 120 minutes prior to the operation (Group A)
Trial: 17405199
Drug: Transdermal anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal anaesthesia using EMLA (Group A)
Trial: 10991932
Drug: L-NAME, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME, 1 micromol per nostril every 30 min for 6 h
Trial: 10991932
Drug: L-arginine, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine, 30 micromol
Trial: 10991932
Drug: L-NMMA, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA, 1 micromol
Trial: 10991932
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of L-NAME, 1 micromol
Trial: 3468098
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin
Trial: 3546155
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ofloxacin
Trial: 29777864
Drug: Home‐based dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home‐based dietary counseling +800 mg/day DHA supplementation
Trial: 29777864
Drug: 800 mg/day DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day DHA
Trial: 29777864
Drug: Home‐based dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home‐based dietary counseling +200 mg/day DHA
Trial: 29777864
Drug: 200 mg/day DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day DHA
Trial: 24939437
Drug: α-Lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-Lipoic acid (ALA) (100 mg/day)
Trial: 21992977
Drug: Lactobacillus crispatus
RxNorm normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus crispatus CTV-05 (LACTIN-V) applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Trial: 21992977
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Trial: 21992977
Drug: Endogenous L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous L. crispatus presence
Trial: 14634680
Drug: PEG‐OB protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐OB protein (80 mg) administered subcutaneously weekly for 6 weeks
Trial: 14634680
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously weekly for 6 weeks
Trial: 14634680
Drug: PEG‐OB protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐OB protein (80 mg)
Trial: 8877657
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Braun/Oral-B Plak Control)
Trial: 6109119
Drug: Dry artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry artificial lung surfactant (one dose)
Trial: 26370443
Drug: 600 mcg
RxNorm normalized name: Biotin 600 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mcg misoprostol
Trial: 23469256
Drug: Pregabalin (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150-300 mg BID)
Trial: 21441812
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) in combination with a probiotic
Trial: 15513446
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG) combined with feeder vessel treatment (FVT)
Trial: 15513446
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG)
Trial: 28271568
Drug: Ziziphus jujube
RxNorm normalized name: Ziziphus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziziphus jujube fruit (ZJF) infusion (10 g/100 mL boiling water) three times/day before main meals for 12 weeks
Trial: 20528210
Drug: Flutamide-metformin
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide-metformin
Trial: 20528210
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with ethinylestradiol-drospirenone and flutamide-metformin
Trial: 18931625
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (IT) - fixed 8‐week off, 8‐week on regimen
Trial: 18931625
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment (CT) - maintain current treatment strategy
Trial: 18931625
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment (CT)
Trial: 16820341
Drug: CGA (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGA (140 mg/day) from green coffee bean extract
Trial: 14968473
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of elemental zinc for 3 months
Trial: 1590494
Drug: Focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused cognitive therapy for 12 weeks
Trial: 1590494
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to focused cognitive therapy for 12 weeks
Trial: 6084394
Drug: 2.5% phenylpropanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% phenylpropanolamine (PPA) solution
Trial: 26515839
Drug: Twice-weekly targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly targeted ultraviolet B phototherapy
Trial: 26515839
Drug: Once-weekly targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly targeted ultraviolet B phototherapy
Trial: 24229746
Drug: Memantine (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (flexible dose 5-20 mg/d, all reaching 20 mg/d)
Trial: 15022581
Drug: Dexamethasone for
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone for five days (12 mg single dose)
Trial: 15022581
Drug: Dexamethasone less
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone less than five days (12 mg single dose)
Trial: 10964582
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (Neoral), administered once, dosage not specified
Trial: 10964582
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered once, matching CsA
Trial: 1308265
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + Gentamycin postoperatively
Trial: 3872001
Drug: Alcuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.25 mg X kg b.w.‐1 with high-dose fentanyl
Trial: 3872001
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg X kg b.w.‐1 with high-dose fentanyl
Trial: 3872001
Drug: Alcuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.25 mg X kg b.w.‐1 with balanced anaesthesia
Trial: 3872001
Drug: Pancuronium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.05 mg X kg b.w.‐1 + alcuronium 0.125 mg X kg b.w.‐1
Trial: 3872001
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg X kg b.w.‐1
Trial: 3872001
Drug: Alcuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.25 mg X kg b.w.‐1
Trial: 28840591
Drug: Regular drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular drug-eluting stents (rDES)
Trial: 25215468
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplementation (arginine, glutamine, HMB) twice daily for 2 weeks
Trial: 20059663
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy treatment (manual therapy, biofeedback, electrical stimulation, dilator insertions, and home exercises) for women with PVD after 8 sessions
Trial: 17512098
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 23 valent pneumococcal vaccine
Trial: 17512098
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 23 valent pneumococcal vaccine
Trial: 17512098
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection compared to intramuscular injection
Trial: 17512098
Drug: Pre‐vaccination antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐vaccination antibody titres >1 microg/ml
Trial: 17512098
Drug: Female gender
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Female gender with subcutaneous injection
Trial: 11824861
Drug: COER-24 verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER-24 verapamil 240 mg/day titrated to 360 mg/day
Trial: 11824861
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg/day titrated to 20 mg/day
Trial: 11824861
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/day titrated to 100 mg/day
Trial: 11008892
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg b.i.d. oral nilvadipine for 4 weeks
Trial: 8618108
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (AMC) 500/125mg tid for 7 days
Trial: 8618108
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (AMC)